Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Chemical drugs | 1 |
Synthetic peptide | 1 |
Target |
Mechanism KRAS inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism A1R agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism HDAC2 inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date18 Jan 2024 |
Sponsor / Collaborator |
Start Date01 Nov 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
AZ-1569 ( KRAS ) | Colorectal Cancer More | Preclinical |
MRS-7469 ( A1R ) | Central Nervous System Diseases More | Preclinical |
PA-PLA2(Queen's University Belfast) ( Akt x HDAC2 x RIPK1 x c-Myc ) | Lymphoid Leukemia More | Preclinical |
QUB-1813 ( Serine protease ) | Respiratory Tract Infections More | Discovery |